Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 146

1.

Diagnostic and prognostic value of circulating lncRNA H19 in gastric cancer.

Yörüker EE, Keskin M, Kulle CB, Holdenrieder S, Gezer U.

Biomed Rep. 2018 Aug;9(2):181-186. doi: 10.3892/br.2018.1116. Epub 2018 Jun 22.

2.

Circulating microRNAs are associated with Pulmonary Hypertension and Development of Chronic Lung Disease in Congenital Diaphragmatic Hernia.

Herrera-Rivero M, Zhang R, Heilmann-Heimbach S, Mueller A, Bagci S, Dresbach T, Schröder L, Holdenrieder S, Reutter HM, Kipfmueller F.

Sci Rep. 2018 Jul 16;8(1):10735. doi: 10.1038/s41598-018-29153-8.

3.

Improved sensitivity for detection of breast cancer by combination of miR-34a and tumor markers CA 15-3 or CEA.

Zaleski M, Kobilay M, Schroeder L, Debald M, Semaan A, Hettwer K, Uhlig S, Kuhn W, Hartmann G, Holdenrieder S.

Oncotarget. 2018 Apr 27;9(32):22523-22536. doi: 10.18632/oncotarget.25077. eCollection 2018 Apr 27.

4.

Technical and clinical performance of a new assay to detect squamous cell carcinoma antigen levels for the differential diagnosis of cervical, lung, and head and neck cancer.

Holdenrieder S, Molina R, Qiu L, Zhi X, Rutz S, Engel C, Kasper-Sauer P, Dayyani F, Korse CM.

Tumour Biol. 2018 Apr;40(4):1010428318772202. doi: 10.1177/1010428318772202.

PMID:
29701125
5.

Comparison of Carbohydrate Antigen 125 and N-Terminal Pro-Brain Natriuretic Peptide for Risk Prediction After Transcatheter Aortic Valve Implantation.

Rheude T, Pellegrini C, Schmid H, Trenkwalder T, Mayr NP, Joner M, Kasel AM, Holdenrieder S, Nunez J, Sanchis J, Bodi V, Schunkert H, Kastrati A, Hengstenberg C, Husser O.

Am J Cardiol. 2018 Feb 15;121(4):461-468. doi: 10.1016/j.amjcard.2017.11.020. Epub 2017 Nov 27.

PMID:
29306485
6.

Determinants of elevated carbohydrate antigen 125 in patients with severe symptomatic aortic valve stenosis referred for transcatheter aortic valve implantation.

Rheude T, Pellegrini C, Reinhard W, Trenkwalder T, Koenig W, Mayr NP, Joner M, Núñez J, Holdenrieder S, Schunkert H, Kastrati A, Hengstenberg C, Husser O.

Biomarkers. 2018 May;23(3):299-304. doi: 10.1080/1354750X.2018.1423706. Epub 2018 Jan 15.

PMID:
29297708
7.

Evaluation of cellulose pads as a method to detect cytomegalovirus DNA in neonatal urine.

Kipfmueller F, Jungbluth K, Eis-Hübinger AM, Reber U, Holdenrieder S, Gembruch U, Bartmann P, Mueller A.

Ann Clin Biochem. 2018 Jan 1:4563217750183. doi: 10.1177/0004563217750183. [Epub ahead of print]

PMID:
29216741
8.

A comparison of gamma-glutamyl transferase and alkaline phosphatase as prognostic markers in patients with coronary heart disease.

Ndrepepa G, Holdenrieder S, Cassese S, Fusaro M, Xhepa E, Laugwitz KL, Schunkert H, Kastrati A.

Nutr Metab Cardiovasc Dis. 2018 Jan;28(1):64-70. doi: 10.1016/j.numecd.2017.09.005. Epub 2017 Sep 23.

PMID:
29126670
9.

Circular RNA maps paving the road to biomarker development?

Görlach A, Holdenrieder S.

J Mol Med (Berl). 2017 Nov;95(11):1137-1141. doi: 10.1007/s00109-017-1603-8. No abstract available.

PMID:
29067477
10.

Clinical performance of LOCI™-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers.

Dolscheid-Pommerich RC, Keyver-Paik M, Hecking T, Kuhn W, Hartmann G, Stoffel-Wagner B, Holdenrieder S.

Tumour Biol. 2017 Oct;39(10):1010428317730246. doi: 10.1177/1010428317730246.

PMID:
29034816
11.

[Multicenter Evaluation of A New Progastrin-releasing Peptide (ProGRP) Immunoassay across Europe and China].

Korse CM, Holdenrieder S, Zhi X, Zahng X, Qiu L, Geistanger A, Lisy MR, Wehnl B, Broek DVD, Escudero JM, Standop J, Hu M, Molina R.

Zhongguo Fei Ai Za Zhi. 2017 Aug 20;20(8):568-577. doi: 10.3779/j.issn.1009-3419.2017.08.12. Chinese.

12.

Soluble ST2 for Risk Stratification and the Prediction of Mortality in Patients Undergoing Transcatheter Aortic Valve Implantation.

Stundl A, Lünstedt NS, Courtz F, Freitag-Wolf S, Frey N, Holdenrieder S, Zur B, Grube E, Nickenig G, Werner N, Frank D, Sinning JM.

Am J Cardiol. 2017 Sep 15;120(6):986-993. doi: 10.1016/j.amjcard.2017.06.033. Epub 2017 Jun 29.

PMID:
28739033
13.

Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer.

Kruger S, Legenstein ML, Rösgen V, Haas M, Modest DP, Westphalen CB, Ormanns S, Kirchner T, Heinemann V, Holdenrieder S, Boeck S.

Oncoimmunology. 2017 Mar 31;6(5):e1310358. doi: 10.1080/2162402X.2017.1310358. eCollection 2017.

14.

Diagnostic relevance of a novel multiplex immunoassay panel in breast cancer.

Hermann N, Dressen K, Schroeder L, Debald M, Schildberg FA, Walgenbach-Bruenagel G, Hettwer K, Uhlig S, Kuhn W, Hartmann G, Holdenrieder S.

Tumour Biol. 2017 Jun;39(6):1010428317711381. doi: 10.1177/1010428317711381.

PMID:
28618926
15.

Prognostic value of alkaline phosphatase in patients with acute coronary syndromes.

Ndrepepa G, Holdenrieder S, Xhepa E, Cassese S, Fusaro M, Laugwitz KL, Schunkert H, Kastrati A.

Clin Biochem. 2017 Oct;50(15):828-834. doi: 10.1016/j.clinbiochem.2017.05.020. Epub 2017 Jun 1.

PMID:
28579339
16.

The Impact of SMAD4 Loss on Outcome in Patients with Advanced Pancreatic Cancer Treated with Systemic Chemotherapy.

Ormanns S, Haas M, Remold A, Kruger S, Holdenrieder S, Kirchner T, Heinemann V, Boeck S.

Int J Mol Sci. 2017 May 19;18(5). pii: E1094. doi: 10.3390/ijms18051094.

17.

Free-Circulating Methylated DNA in Blood for Diagnosis, Staging, Prognosis, and Monitoring of Head and Neck Squamous Cell Carcinoma Patients: An Observational Prospective Cohort Study.

Schröck A, Leisse A, de Vos L, Gevensleben H, Dröge F, Franzen A, Wachendörfer M, Schröck F, Ellinger J, Teschke M, Wilhelm-Buchstab T, Landsberg J, Holdenrieder S, Hartmann G, Field JK, Bootz F, Kristiansen G, Dietrich D.

Clin Chem. 2017 Jul;63(7):1288-1296. doi: 10.1373/clinchem.2016.270207. Epub 2017 May 17.

18.

Diagnostic Performance of a Novel Multiplex Immunoassay in Colorectal Cancer.

Dressen K, Hermann N, Manekeller S, Walgenbach-Bruenagel G, Schildberg FA, Hettwer K, Uhlig S, Kalff JC, Hartmann G, Holdenrieder S.

Anticancer Res. 2017 May;37(5):2477-2486.

PMID:
28476816
19.

Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis.

Holdenrieder S, Wehnl B, Hettwer K, Simon K, Uhlig S, Dayyani F.

Br J Cancer. 2017 Apr 11;116(8):1037-1045. doi: 10.1038/bjc.2017.45. Epub 2017 Mar 9. Review.

20.

Clinically Meaningful Use of Blood Tumor Markers in Oncology.

Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F.

Biomed Res Int. 2016;2016:9795269. doi: 10.1155/2016/9795269. Epub 2016 Nov 30. Review.

21.

Clinical Performance of CEA, CA19-9, CA15-3, CA125 and AFP in Gastrointestinal Cancer Using LOCI™-based Assays.

Dolscheid-Pommerich RC, Manekeller S, Walgenbach-Brünagel G, Kalff JC, Hartmann G, Wagner BS, Holdenrieder S.

Anticancer Res. 2017 Jan;37(1):353-359.

PMID:
28011514
22.

Immune checkpoint therapy for pancreatic cancer.

Johansson H, Andersson R, Bauden M, Hammes S, Holdenrieder S, Ansari D.

World J Gastroenterol. 2016 Nov 21;22(43):9457-9476. Review.

23.

Academia Meets Industry.

Schäfer C, Paprotka T, Heitzer E, Eccleston M, Noe J, Holdenrieder S, Diehl F, Thierry A.

Adv Exp Med Biol. 2016;924:201-215.

PMID:
27753044
24.
25.

Paradoxical Role of HMGB1 in Pancreatic Cancer: Tumor Suppressor or Tumor Promoter?

Cebrián MJ, Bauden M, Andersson R, Holdenrieder S, Ansari D.

Anticancer Res. 2016 Sep;36(9):4381-9. Review.

PMID:
27630273
26.

Biomarkers along the continuum of care in lung cancer.

Holdenrieder S.

Scand J Clin Lab Invest Suppl. 2016;245:S40-5. doi: 10.1080/00365513.2016.1208446. Review.

PMID:
27542002
27.

A liposomal formulation of the synthetic curcumin analog EF24 (Lipo-EF24) inhibits pancreatic cancer progression: towards future combination therapies.

Bisht S, Schlesinger M, Rupp A, Schubert R, Nolting J, Wenzel J, Holdenrieder S, Brossart P, Bendas G, Feldmann G.

J Nanobiotechnology. 2016 Jul 11;14(1):57. doi: 10.1186/s12951-016-0209-6.

28.

Prospective, Multicenter Study of 5-Fluorouracil Therapeutic Drug Monitoring in Metastatic Colorectal Cancer Treated in Routine Clinical Practice.

Wilhelm M, Mueller L, Miller MC, Link K, Holdenrieder S, Bertsch T, Kunzmann V, Stoetzer OJ, Suttmann I, Braess J, Birkmann J, Roessler M, Moritz B, Kraff S, Salamone SJ, Jaehde U.

Clin Colorectal Cancer. 2016 Dec;15(4):381-388. doi: 10.1016/j.clcc.2016.04.001. Epub 2016 May 7.

PMID:
27256667
29.

Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) - study protocol for a pragmatic randomized controlled trial.

Stingl JC, Kaumanns KL, Claus K, Lehmann ML, Kastenmüller K, Bleckwenn M, Hartmann G, Steffens M, Wirtz D, Leuchs AK, Benda N, Meier F, Schöffski O, Holdenrieder S, Coch C, Weckbecker K.

BMC Fam Pract. 2016 Apr 26;17:49. doi: 10.1186/s12875-016-0447-6.

30.

Circulating HMGB1 and RAGE as Clinical Biomarkers in Malignant and Autoimmune Diseases.

Pilzweger C, Holdenrieder S.

Diagnostics (Basel). 2015 Jun 16;5(2):219-53. doi: 10.3390/diagnostics5020219. Review.

31.

In Response to "Serum Tumor Marker Use in Patients With Advanced Solid Tumors".

Dayyani F, Morgenstern D, Holdenrieder S.

J Oncol Pract. 2016 Mar;12(3):273-4. doi: 10.1200/JOP.2015.009241. Epub 2016 Feb 2. No abstract available.

PMID:
26837562
32.

Blood-based biomarkers for diagnosis, prognosis and treatment of colorectal cancer.

Yörüker EE, Holdenrieder S, Gezer U.

Clin Chim Acta. 2016 Apr 1;455:26-32. doi: 10.1016/j.cca.2016.01.016. Epub 2016 Jan 18. Review.

PMID:
26797671
33.

Histone Methylation Marks on Circulating Nucleosomes as Novel Blood-Based Biomarker in Colorectal Cancer.

Gezer U, Yörüker EE, Keskin M, Kulle CB, Dharuman Y, Holdenrieder S.

Int J Mol Sci. 2015 Dec 11;16(12):29654-62. doi: 10.3390/ijms161226180.

34.

Apoptosis-related biomarkers in patients with gastrointestinal cancer.

Dressen K, Hermann N, Manekeller S, Walgenbach-Bruenagel G, Schildberg FA, Hettwer K, Uhlig S, Kalff JC, Holdenrieder S.

Int J Clin Pharmacol Ther. 2015 Dec;53(12):1062-4. doi: 10.5414/CPCES14EA11. No abstract available.

35.

Apoptosis-related biomarkers in patients with gynecological cancer.

Hermann N, Dressen K, Schroeder L, Debald M, Keyver-Paik M, Abramian A, Walgenbach-Bruenagel G, Schildberg FA, Hettwer K, Uhlig S, Kuhn W, Holdenrieder S.

Int J Clin Pharmacol Ther. 2015 Dec;53(12):1059-61. doi: 10.5414/CPCES14EA10. No abstract available.

PMID:
26521925
36.

Immune- and miRNA-response to recombinant interferon beta-1a: a biomarker evaluation study to guide the development of novel type I interferon- based therapies.

Coenen M, Hinze AV, Mengel M, Fuhrmann C, Lüdenbach B, Zimmermann J, Dykstra V, Fimmers R, Viviani R, Stingl J, Holdenrieder S, Müller M, Hartmann G, Coch C.

BMC Pharmacol Toxicol. 2015 Sep 22;16:25. doi: 10.1186/s40360-015-0025-x.

37.

Risk scores and biomarkers for the prediction of 1-year outcome after transcatheter aortic valve replacement.

Sinning JM, Wollert KC, Sedaghat A, Widera C, Radermacher MC, Descoups C, Hammerstingl C, Weber M, Stundl A, Ghanem A, Widder J, Vasa-Nicotera M, Mellert F, Schiller W, Bauersachs J, Zur B, Holdenrieder S, Welz A, Grube E, Pencina MJ, Nickenig G, Werner N, Kempf T.

Am Heart J. 2015 Oct;170(4):821-9. doi: 10.1016/j.ahj.2015.07.003. Epub 2015 Jul 10.

PMID:
26386807
38.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

39.

Assessment of circulating serum DNA integrity in colorectal cancer patients.

Yörüker EE, Özgür E, Keskin M, Dalay N, Holdenrieder S, Gezer U.

Anticancer Res. 2015 Apr;35(4):2435-40.

PMID:
25862911
40.

Androgen Stimulation of PCA3 and miR-141 and Their Release from Prostate Cancer Cells.

Gezer U, Tiryakioglu D, Bilgin E, Dalay N, Holdenrieder S.

Cell J. 2015 Winter;16(4):488-93. Epub 2015 Jan 13.

41.

Analysis of tissue and serum microRNA expression in patients with upper urinary tract urothelial cancer.

Kriebel S, Schmidt D, Holdenrieder S, Goltz D, Kristiansen G, Moritz R, Fisang C, Müller SC, Ellinger J.

PLoS One. 2015 Jan 28;10(1):e0117284. doi: 10.1371/journal.pone.0117284. eCollection 2015.

42.

Methodical and pre-analytical characteristics of a multiplex cancer biomarker immunoassay.

Hermann N, Dreßen K, Schildberg FA, Jakobs C, Holdenrieder S.

World J Methodol. 2014 Dec 26;4(4):219-31. doi: 10.5662/wjm.v4.i4.219. eCollection 2014 Dec 26.

43.

Assessing novel prognostic serum biomarkers in advanced pancreatic cancer: the role of CYFRA 21-1, serum amyloid A, haptoglobin, and 25-OH vitamin D3.

Haas M, Kern C, Kruger S, Michl M, Modest DP, Giessen C, Schulz C, von Einem JC, Ormanns S, Laubender RP, Holdenrieder S, Heinemann V, Boeck S.

Tumour Biol. 2015 Apr;36(4):2631-40. doi: 10.1007/s13277-014-2885-x. Epub 2014 Dec 4.

PMID:
25472579
44.

Characterizing the genetic basis of innate immune response in TLR4-activated human monocytes.

Kim S, Becker J, Bechheim M, Kaiser V, Noursadeghi M, Fricker N, Beier E, Klaschik S, Boor P, Hess T, Hofmann A, Holdenrieder S, Wendland JR, Fröhlich H, Hartmann G, Nöthen MM, Müller-Myhsok B, Pütz B, Hornung V, Schumacher J.

Nat Commun. 2014 Oct 20;5:5236. doi: 10.1038/ncomms6236.

PMID:
25327457
45.

[Detection of cell-free lncRNA in serum of cancer patients].

Kohls K, Schmidt D, Holdenrieder S, Müller SC, Ellinger J.

Urologe A. 2015 Jun;54(6):819-25. doi: 10.1007/s00120-014-3655-5. German.

PMID:
25312755
46.

Multicenter evaluation of a new progastrin-releasing peptide (ProGRP) immunoassay across Europe and China.

Korse CM, Holdenrieder S, Zhi XY, Zhang X, Qiu L, Geistanger A, Lisy MR, Wehnl B, van den Broek D, Escudero JM, Standop J, Hu M, Molina R.

Clin Chim Acta. 2015 Jan 1;438:388-95. doi: 10.1016/j.cca.2014.09.015. Epub 2014 Sep 28.

47.

Serum autoantibody measurement for the detection of hepatocellular carcinoma.

Middleton CH, Irving W, Robertson JF, Murray A, Parsy-Kowalska CB, Macdonald IK, McElveen J, Allen J, Healey GF, Thomson BJ, Ryder SJ, Holdenrieder S, Chapman CJ.

PLoS One. 2014 Aug 5;9(8):e103867. doi: 10.1371/journal.pone.0103867. eCollection 2014.

48.

Circulating nucleosomes: a new addition to the personalized medicine toolkit.

Holdenrieder S.

Per Med. 2014 Aug;11(6):565-568. doi: 10.2217/pme.14.47.

49.

Circulating serum miRNA (miR-367-3p, miR-371a-3p, miR-372-3p and miR-373-3p) as biomarkers in patients with testicular germ cell cancer.

Syring I, Bartels J, Holdenrieder S, Kristiansen G, Müller SC, Ellinger J.

J Urol. 2015 Jan;193(1):331-7. doi: 10.1016/j.juro.2014.07.010. Epub 2014 Jul 18.

PMID:
25046619
50.

Increased DNA integrity in colorectal cancer.

Leszinski G, Lehner J, Gezer U, Holdenrieder S.

In Vivo. 2014 May-Jun;28(3):299-303.

PMID:
24815830

Supplemental Content

Loading ...
Support Center